UK markets closed

Inozyme Pharma, Inc. (INZY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.5400-0.1100 (-2.37%)
At close: 04:00PM EDT
4.5500 +0.01 (+0.22%)
After hours: 07:28PM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
0
0
0
0
0
Operating expenses
Research development
62,101
54,847
47,849
37,720
46,493
Selling general and administrative
19,520
20,798
20,826
18,926
10,548
Total operating expenses
81,621
75,645
68,675
56,646
57,041
Operating income or loss
-81,621
-75,645
-68,675
-56,646
-57,041
Interest expense
4,330
3,333
262
-
-
Total other income/expenses net
-45
-28
-319
-189
247
Income before tax
-77,112
-71,169
-67,061
-56,624
-56,424
Income from continuing operations
-77,112
-71,169
-67,061
-56,624
-56,424
Net income
-77,112
-71,169
-67,061
-56,624
-56,424
Net income available to common shareholders
-77,112
-71,169
-67,061
-56,624
-56,424
Basic EPS
-1.44
-
-1.78
-1.78
-5.11
Diluted EPS
-1.44
-
-1.78
-1.78
-5.11
Basic average shares
47,317
-
37,763
23,558
11,037
Diluted average shares
47,317
-
37,763
23,558
11,037